Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 997,545
  • Shares Outstanding, K 67,768
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,590 K
  • EBIT $ -79 M
  • EBITDA $ -78 M
  • 60-Month Beta 1.69
  • Price/Sales 11,291.35
  • Price/Cash Flow N/A
  • Price/Book 10.65

Options Overview Details

View History
  • Implied Volatility 246.27% (+46.21%)
  • Historical Volatility 47.52%
  • IV Percentile 90%
  • IV Rank 62.01%
  • IV High 352.51% on 11/20/25
  • IV Low 72.89% on 02/06/25
  • Expected Move (DTE 7) 1.62 (10.97%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 1,627
  • Open Int (30-Day) 1,605
  • Expected Range 13.11 to 16.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -18.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.17 +11.77%
on 01/02/26
15.96 -7.77%
on 12/22/25
+1.23 (+9.12%)
since 12/08/25
3-Month
12.56 +17.20%
on 11/20/25
20.00 -26.42%
on 10/09/25
-5.22 (-26.18%)
since 10/08/25
52-Week
12.56 +17.20%
on 11/20/25
25.00 -41.12%
on 02/05/25
-3.71 (-20.13%)
since 01/08/25

Most Recent Stories

More News
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

HYPR : 0.9914 (-0.86%)
OFIX : 16.20 (+2.99%)
SPNC : 38.45 (unch)
AVNS : 12.26 (+4.79%)
PLSE : 14.72 (-3.16%)
SWAV : 334.75 (-0.02%)
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond...

PLSE : 14.72 (-3.16%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 14.72 (-3.16%)
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure

PLSE : 14.72 (-3.16%)

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 16.42
2nd Resistance Point 16.03
1st Resistance Point 15.38
Last Price 14.72
1st Support Level 14.33
2nd Support Level 13.94
3rd Support Level 13.29

See More

52-Week High 25.00
Fibonacci 61.8% 20.25
Fibonacci 50% 18.78
Fibonacci 38.2% 17.31
Last Price 14.72
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar